Gin S. Malhi

Active 1999–2025

167
Papers
34,474
Citations
97
h-index
162
i10-index

Citations

Citations per year for Gin S. Malhi1983: 1 citations1987: 1 citations1991: 1 citations1999: 1 citations2000: 4 citations2001: 11 citations2002: 9 citations2003: 15 citations2004: 40 citations2005: 73 citations2006: 71 citations2007: 131 citations2008: 170 citations2009: 251 citations2010: 295 citations2011: 333 citations2012: 387 citations2013: 394 citations2014: 412 citations2015: 318 citations2016: 275 citations2017: 268 citations2018: 230 citations2019: 889 citations2020: 1,210 citations2021: 1,112 citations2022: 954 citations2023: 758 citations2024: 1,213 citations2025: 501 citations2026: 22 citations1984–1986: no citations, so these years are not shown1988–1990: no citations, so these years are not shown1992–1998: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,539 citing papers, 18.2% of this breakdownChina: 1,569 citing papers, 11.3% of this breakdownUnited Kingdom: 1,065 citing papers, 7.6% of this breakdownAustralia: 951 citing papers, 6.8% of this breakdownCanada: 881 citing papers, 6.3% of this breakdownItaly: 689 citing papers, 5% of this breakdownGermany: 644 citing papers, 4.6% of this breakdownSpain: 541 citing papers, 3.9% of this breakdownBrazil: 493 citing papers, 3.5% of this breakdownNetherlands: 370 citing papers, 2.7% of this breakdownFrance: 328 citing papers, 2.4% of this breakdownJapan: 255 citing papers, 1.8% of this breakdown
0%18.2%Other 25.9%

Fields

  • Medicine47.6%
  • Neuroscience28.4%
  • Psychology12.5%
  • Biochemistry, Genetics and Molecular Biology6.5%
  • Health Professions1%
  • Environmental Science0.5%
  • Other3.5%

Topics

  • Bipolar Disorder and Treatment11%
  • Tryptophan and brain disorders7.7%
  • Schizophrenia research and treatment5.3%
  • Treatment of Major Depression5.1%
  • Functional Brain Connectivity Studies3.8%
  • Stress Responses and Cortisol3.1%
  • Other64%

Coauthors

All papers

Open in search
  1. Depression

    Authors: , - The Lancet 2018 cited by 3,985

  2. Bipolar disorders

    Authors: , , , , , , , , , , , , , - The Lancet 2020 cited by 981

  3. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Bipolar Disorders 2018 cited by 1,770

  4. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders

    Authors: , , , , , , , , , , , - Australian & New Zealand Journal of Psychiatry 2020 cited by 580

  5. Common and distinct patterns of grey-matter volume alteration in major depression and bipolar disorder: evidence from voxel-based meta-analysis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sudhakar Selvaraj, Andrew C. Stanfield, Alan Thomas, Marie‐José van Tol, Nic J.A. van der Wee, Dick J. Veltman, Allan H. Young, Cynthia H.Y. Fu, Anthony J. Cleare, Danilo Arnone - Molecular Psychiatry 2016 cited by 620

  6. Increased Theta and Alpha EEG Activity During Nondirective Meditation

    Authors: , , , , , , , , , , , - The Journal of Alternative and Complementary Medicine 2009 cited by 354

  7. Prevalence of comorbid substance use in major depressive disorder in community and clinical settings, 1990–2019: Systematic review and meta-analysis

    Authors: , , , - Journal of Affective Disorders 2020 cited by 274

  8. Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors

    Authors: , , , , , , , , , , , , , - Neuroscience & Biobehavioral Reviews 2010 cited by 1,169

  9. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders

    Authors: , , , , , , , , , , , - Australian & New Zealand Journal of Psychiatry 2015 cited by 854

  10. The identification, assessment and management of difficult-to-treat depression: An international consensus statement

    Authors: , , , , , , , , , , , , , , - Journal of Affective Disorders 2020 cited by 272

  11. The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Frederick Cassidy, Hagop S. Akiskal, Jean-Michel Azorin, Marc Valentí, Diego Hidalgo‐Mazzei, Beny Lafer, Tadafumi Kato, Lorenzo Mazzarini, Anabel Martínez‐Arán, Gordon Parker, Daniel Souery, Ayşegül Özerdem, Susan L. McElroy, Paolo Girardi, Michael Bauer, Lakshmi N. Yatham, Carlos A. Zarate, Andrew A. Nierenberg, Boris Birmaher, Shigenobu Kanba, Rif S. El‐Mallakh, Alessandro Serretti, Zoltán Rihmer, Allan H. Young, Georgios D. Kotzalidis, Glenda MacQueen, Charles L. Bowden, S. Nassir Ghaemi, Carlos López‐Jaramillo, Janusz Rybakowski, Kyooseob Ha, Giulio Perugi, Siegfried Kasper, Jay D. Amsterdam, Robert M. A. Hirschfeld, Flávio Kapczinski, Eduard Vieta - American Journal of Psychiatry 2013 cited by 754

  12. Potential Mechanisms of Action of Lithium in Bipolar Disorder

    Authors: , , , , - CNS Drugs 2013 cited by 446

  13. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: Major depression summary

    Authors: , , , , , , , , , , , , , , , , , , - Bipolar Disorders 2020 cited by 119

  14. Mental health care for university students: a way forward?

    Authors: , , , , , , , - The Lancet Psychiatry 2019 cited by 255

  15. A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don’t work well enough?

    Authors: , , , , , , , , , , , , , , , , , , , , - The World Journal of Biological Psychiatry 2020 cited by 87

  16. The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders

    Authors: , , , , , , , , , , , , , , , , , , - Bipolar Disorders 2009 cited by 507

  17. N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility

    Authors: , , , , - Expert Opinion on Biological Therapy 2008 cited by 407

  18. The promise of N-acetylcysteine in neuropsychiatry

    Authors: , , , - Trends in Pharmacological Sciences 2013 cited by 422

  19. Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder

    Authors: , , , , , , - Acta Psychiatrica Scandinavica 2007 cited by 394

  20. The limitations of using randomised controlled trials as a basis for developing treatment guidelines

    Authors: , , , , , , , , , , , , - Evidence-Based Mental Health 2017 cited by 111

  21. Default-mode and fronto-parietal network connectivity during rest distinguishes asymptomatic patients with bipolar disorder and major depressive disorder

    Authors: , , , , , , , , , , - Translational Psychiatry 2021 cited by 78

  22. A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo

    Authors: , , , , , , , , , , , , , , - BMC Medicine 2019 cited by 99

  23. Prevalence of comorbid bipolar and substance use disorders in clinical settings, 1990–2015: Systematic review and meta-analysis

    Authors: , , , , - Journal of Affective Disorders 2016 cited by 235

  24. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - 2019 cited by 219